Kemp Proteins, a leading provider of gene-to-protein and monoclonal antibody development services, announced today that the company has appointed Carter Michell, Ph.D. as its new Chief Scientific Officer (CSO). Carter will lead the scientific and technological development of Kemp Proteins as the company continues its impressive growth following its purchase by Six02 Bioservices in January 2019.
The coronavirus pandemic has had profound negative impacts on large swaths of the U.S. economy. However, certain sectors like the life sciences have remained steady or have even grown, as many of these companies have pivoted to producing COVID-19-related tests, materials, therapeutics, and vaccines.
Photo Credit: Will Kirk / Johns Hopkins University Good News Stories Emerging from the Capital Region Show Solidarity Amid Coronavirus Endless social media scrolls, 24/7 news channels, newspapers, and radio [….]
BaneBio invites members of the biotech community in Frederick County and beyond to attend our BioBeers event on March 13, 2020! Bring your friends and coworkers and join us for [….]
Advancements In Gene Editing and CRISPR Emerging From Frederick, Maryland’s Vibrant BioHub A strong crowd of BioHealth Capital Region (BHCR) lab researchers, genomic scientists, and other life science industry members [….]
Five Cell and Gene Therapy Companies that Are Changing the Landscape of the Field
Growth at Frederick Community College’s Biotechnology Program Mirrors Thriving Industry Frederick Community College’s (FCC) Biotechnology Program continues to forge new partnerships and grow its capabilities to support Frederick’s thriving biotechnology [….]
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
Kite opens Gaithersburg, Maryland R&D Facility